Cytek expanded Cloud Analysis. Cytek Biosciences stock traded at EUR 4.74 below EUR 4.77

Published on 10/08/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytek Cloud had more than 28,000 users on September 23, 2026. Cytek Biosciences stock cost EUR 4.74 on October 8, 2026 versus EUR 4.77.

CTKB, US23285D1090, Illustration mit AI erstellt.

Cytek Biosciences (ISIN US23285D1090) was trading at EUR 4.74 at Lang & Schwarz on October 8, 2026 at 10:59 a.m. CEST, below the EUR 4.77 prior close. On September 23, 2026, GlobeNewswire reported that Cytek had expanded Cytek Cloud with a Cloud Analysis tool.

Cloud Analysis broadens the platform

The September 23, 2026 release added online data analysis and storage to Cytek Cloud, extending the workflow from panel design and experiment setup through data acquisition and analysis. The platform had more than 28,000 users and double-digit year-over-year user growth at the time of the announcement, according to GlobeNewswire.

Cytek also introduced a Premium subscription tier with Cloud Analysis and online storage. Premium was available to customers in the United States, while Basic and Pro plans covered lower levels of functionality.

Revenue beat expectations in the second quarter

Cytek reported USD 48.14 million of revenue in the second quarter of 2026, versus USD 47.31 million expected by analysts, according to MarketBeat. The comparison represents a USD 0.83 million revenue beat, while the company matched the consensus adjusted earnings-per-share loss of USD 0.09 for the same quarter.

The revenue result offers a useful counterweight to the reported loss. For investors, the combination of platform adoption and recurring software potential matters because the new Premium tier gives Cytek another way to monetize its installed research base.

Analyst target remains near the market

MarketBeat reported on October 6, 2026 that three analysts rated CTKB Buy, two rated it Hold and one rated it Sell. The average price target was USD 5.56, while the same report described a Hold consensus.

MarketBeat also reported a 52-week high of USD 6.21 and a market capitalization of USD 725.81 million on October 6, 2026. Those figures belong to the Nasdaq listing and are separate from the euro quotation used in this article.

Euro quote stays below prior close

Cytek Biosciences stock was trading at EUR 4.74 at Lang & Schwarz on October 8, 2026 at 10:59 a.m. CEST, down 0.63 percent versus the EUR 4.77 Lang & Schwarz prior close of October 7, 2026. The modest intraday decline leaves the software expansion and the second-quarter revenue comparison as the clearest measurable reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Cytek Biosciences stock.